Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
NIVO3+IPI1 versus NIVO1+IPI3 bij gevorderd melanoom: CheckMate 511
apr 2019 | Dermato-oncologie, Immuuntherapie